| Literature DB >> 35990271 |
Susithra Priyadarshni Mugunthan1, Mani Chandra Harish1.
Abstract
Mycoplasma gallisepticum variable lipoprotein hemagglutin (vlhA) proteins are crucial for immune evasion from the host cells, permitting the persistence and survival of the pathogen. However, the exact molecular mechanism behind the immune evasion function is still not clear. In silico physiochemical analysis, domain analysis, subcellular localization, and homology modeling studies have been carried out to predict the structural and functional properties of these proteins. The outcomes of this study provide significant preliminary data for understanding the immune evasion by vlhA proteins. In this study, we have reported the primary, secondary, and tertiary structural characteristics and subcellular localization, presence of the transmembrane helix and signal peptide, and functional characteristics of vlhA proteins from M. gallisepticum strain R low. The results show variation between the structural and functional components of the proteins, signifying the role and diverse molecular mechanisms in functioning of vlhA proteins in host immune evasion. Moreover the 3D structure predicted in this study will pave a way for understanding vlhA protein function and its interaction with other molecules to undergo immune evasion. This study forms the basis for future experimental studies improving our understanding in the molecular mechanisms used by vlhA proteins.Entities:
Keywords: M. gallisepticum; avian mycoplasmosis; bioinformatics; immune evasion; variable lipoprotein hemagglutin
Year: 2022 PMID: 35990271 PMCID: PMC9386052 DOI: 10.3389/fvets.2022.943831
Source DB: PubMed Journal: Front Vet Sci ISSN: 2297-1769
List of vlhA genes based on their group analyzed in this study.
|
|
|
|
|
|
|---|---|---|---|---|
| vlhA.1.01 | vlhA.2.01 | vlhA.3.01 | vlhA.4.01 | vlhA.5.01a |
Figure 1Schematic representation of the workflow followed in this study.
List of bioinformatics tools and servers employed in the structural and functional analyses of vlhA proteins.
|
|
|
|
|
|---|---|---|---|
| 1. | Phylogenetic analysis | Phylogeny.fr |
|
| 2. | Physiochemical properties | ExPASy-Protparam tool |
|
| 3. | Secondary structure | SOPMA |
|
| GOR IV |
| ||
| 4. | Tertiary structure | Raptor X |
|
| I Tasser |
| ||
| 5. | Structure validation | PROCHECK |
|
| QMEAN |
| ||
| 6. | Sub cellular Localization | PSLPRED |
|
| PSORTB |
| ||
| CELLO2GO |
| ||
| 7. | Transmembrane Helix | SOSUI |
|
| HMMTOP |
| ||
| TMHMM |
| ||
| 8. | Signal peptide | Signal p |
|
| Target p |
| ||
| 9. | Functional Domain | CDD- BLAST |
|
| HmmScan |
| ||
| Pfam |
| ||
| SCANPROSITE |
| ||
| SMART |
|
Figure 2Phylogenetic tree showing the evolutionary relationship of different M. gallisepticum vlhA proteins. The numbers indicate bootstrap percentages and the scale indicates the divergence time.
Figure 3Graphical representation of amino acid composition of M. gallisepticum vlhA proteins. (A) vlhA 1 group, (B) vlhA 2 group, (C) vlhA 3 group, (D) vlhA 4 group, and (E) vlhA group 5.
Physiochemical properties like number of amino acids, molecular weight, isoelectric point, extinction coeffcient, half-life (h), instability index, aliphatic index, and GRAVY of M. gallisepticum vlhA proteins.
|
|
|
|
|
|
|
|
|
|
|---|---|---|---|---|---|---|---|---|
| vlhA.1.01 | 686 | 74.02 | 6.23 | 71,280 | 30 | 26.86 | 67.46 | −0.542 |
| vlhA.1.02 | 666 | 71.65 | 5.3 | 61,200 | 30 | 25.89 | 68.83 | −0.445 |
| vlhA.1.03 | 682 | 72.83 | 5.54 | 63,260 | 30 | 28.14 | 71.85 | −0.385 |
| vlhA.1.04 | 697 | 74.83 | 6.81 | 65,780 | 30 | 32.57 | 68.75 | −0.5 |
| vlhA.1.05 | 730 | 79.70 | 9.08 | 73,690 | 30 | 36.44 | 36.44 | −0.525 |
| vlhA.1.06 | 754 | 80.92 | 6.36 | 62,340 | 30 | 27.55 | 80.44 | −0.329 |
| vlhA.1.07 | 728 | 77.55 | 5.49 | 67,730 | 30 | 30.03 | 69.08 | −0.513 |
| vlhA.1.08 | 98 | 10.21 | 9.25 | 1,490 | 30 | 46.91 | 59.9 | −0.446 |
| vlhA.1.08b | 494 | 53.55 | 5.28 | 53,750 | 30 | 24.5 | 70.71 | −0.414 |
| vlhA.2.01 | 607 | 66.88 | 8.19 | 55,700 | 30 | 41.99 | 85.65 | −0.354 |
| vlhA.2.02 | 582 | 63.10 | 6.79 | 60,740 | 30 | 29.80 | 74.30 | −0.430 |
| vlhA.3.0.1 | 536 | 58.00 | 5.28 | 67,270 | 30 | 26.83 | 68.97 | −0.442 |
| vlhA.3.02 | 646 | 69.75 | 8.37 | 77,700 | 30 | 24.51 | 73.85 | −0.439 |
| vlhA.3.03 | 645 | 69.93 | 5.38 | 68,190 | 30 | 27.6 | 73.35 | −0.389 |
| vlhA.3.04 | 734 | 78.52 | 5.68 | 62,230 | 30 | 26.34 | 69.73 | −0.515 |
| vlhA.3.05 | 708 | 75.77 | 5.36 | 72,770 | 30 | 37.21 | 65.9 | −0.531 |
| vlhA.3.06 | 688 | 73.76 | 6.8 | 72,250 | 30 | 30.51 | 72.63 | −0.427 |
| vlhA.3.07 | 656 | 70.87 | 5.78 | 60,740 | 30 | 231.64 | 72.15 | −0.426 |
| vlhA.3.08 | 692 | 74.76 | 6 | 68,190 | 30 | 33.47 | 68.4 | −0.537 |
| vlhA.3.09 | 707 | 76.06 | 5.68 | 74,260 | 30 | 30.91 | 69.99 | −0.55 |
| vlhA.4.01 | 644 | 69.49 | 8.74 | 69,680 | 30 | 24.79 | 70.51 | −0.415 |
| vlhA.4.02 | 751 | 80.74 | 5.76 | 62,340 | 30 | 27.23 | 76.11 | −0.438 |
| vlhA.4.03a | 197 | 20.71 | 9.06 | 13,075 | 30 | 24.19 | 61.57 | −0.525 |
| vlhA.4.03b | 506 | 55.11 | 6.25 | 63,720 | 30 | 33.38 | 68.64 | −0.523 |
| vlhA.4.04 | 679 | 72.64 | 5.60 | 70,250 | 30 | 26.79 | 71.72 | −0.465 |
| vlhA.4.05 | 673 | 72.27 | 6.01 | 67,270 | 30 | 25.63 | 71.66 | −0.466 |
| vlhA.4.06 | 698 | 74.98 | 5.56 | 74,260 | 30 | 30.59 | 66.85 | −0.545 |
| vlhA.4.07 | 667 | 71.81 | 8.72 | 62,230 | 30 | 30.34 | 67.80 | −0.501 |
| vlhA.4.07.1 | 684 | 73.2 | 7.56 | 70,250 | 30 | 30.66 | 72.35 | −0.424 |
| vlhA.4.07.2 | 191 | 20.1 | 9.21 | 13,075 | 30 | 24.54 | 63.51 | −0.493 |
| vlhA.4.07.4 | 673 | 72.3 | 6.32 | 68,760 | 30 | 25.37 | 71.66 | −0.463 |
| vlhA.4.07.6 | 667 | 71.7 | 8.30 | 62,230 | 30 | 29.85 | 67.80 | −0.496 |
| vlhA.4.08 | 688 | 73.6 | 7.56 | 70,250 | 30 | 30.54 | 71.93 | −0.428 |
| vlhA.4.09 | 710 | 76 | 6.88 | 69,790 | 30 | 31.84 | 65.17 | −0.514 |
| vlhA.4.10 | 795 | 85.3 | 7.52 | 62,340 | 30 | 30.29 | 74.34 | −0.479 |
| vlhA4.11 | 690 | 74 | 6.40 | 61,770 | 30 | 28.52 | 65.82 | −0.544 |
| vlhA.4.12 | 701 | 75.1 | 5.28 | 63,260 | 30 | 27.86 | 27.86 | −0.446 |
| vlhA.5.01a | 212 | 23.32 | 5.10 | 8,940 | 30 | 38.68 | 95.75 | −0.456 |
| vlhA.5.01b | 309 | 33.93 | 4.80 | 47,330 | 30 | 31.19 | 59.35 | −0.431 |
| vlhA.5.01c | 86 | 9.38 | 4.63 | 1,490 | 30 | 41.87 | 44.30 | −0.779 |
| vlhA.5.02 | 610 | 66.45 | 8.51 | 56,270 | 30 | 30.65 | 79.98 | −0.407 |
| vlhA.5.03 | 728 | 77.47 | 8.78 | 67,730 | 30 | 28.91 | 72.15 | −0.449 |
| vlhA.5.04 | 740 | 78.90 | 5.17 | 66,240 | 30 | 35.27 | 69.27 | −0.467 |
| vlhA.5.05 | 644 | 69.83 | 5.73 | 66,700 | 30 | 26.68 | 73.93 | −0.392 |
| vlhA.5.06 | 703 | 75.28 | 5.75 | 65,780 | 30 | 28.52 | 65.82 | −0.544 |
| vlhA.5.07 | 681 | 73.27 | 5.55 | 60,280 | 30 | 30.09 | 71.82 | −0.444 |
| vlhA.5.08 | 661 | 71.41 | 6.32 | 58,220 | 30 | 29.53 | 70.88 | −0.460 |
| vlhA.5.09 | 701 | 75.19 | 6.42 | 67,270 | 30 | 24.61 | 69.83 | −0.531 |
| vlhA.5.10a | 642 | 70.06 | 9.04 | 68,885 | 30 | 26.23 | 68.69 | −0.619 |
| vlhA.5.10b | 77 | 8.12 | 8.03 | 8,480 | 30 | 51.99 | 65.97 | −0.619 |
| vlhA.5.11 | 711 | 75.88 | 6.87 | 69,220 | 30 | 20.48 | 66.03 | −0.55 |
| vlhA.5.12 | 678 | 73.12 | 5.81 | 67,730 | 30 | 25.23 | 71.80 | −0.483 |
| vlhA.5.13 | 616 | 66.94 | 8.89 | 65,210 | 30 | 29.03 | 79.53 | −0.394 |
Figure 4Three-dimensional ab initio models of vlhA proteins. Visualizations of model structures were performed by UCSF Chimera.
Tertiary structural validation- Qmean Score, Ramachandran plot most favored region and functional analysis-Subcellular Localization, Transmembrane helix, Signal peptide of vlhA proteins.
|
|
|
|
|
|
|
|
|---|---|---|---|---|---|---|
| 1 | vlhA.1.01 | −10.78 | 68.1% | Extracellular | 2(44–61)(106–123) | Yes |
| 2 | vlhA.1.02 | −10.06 | 70.2% | Extracellular | 2(42–59)(104–121) | Yes |
| 3 | vlhA.1.03 | −9.32 | 69.3% | Extracellular | 2(42–59)(104–121) | Yes |
| 4 | vlhA.1.04 | −10.62 | 69.6% | Extracellular | 2(42–59)(104–121) | Yes |
| 5 | vlhA.1.05 | −11.63 | 66.3% | Extracellular | 0 | Yes |
| 6 | vlhA.1.06 | −7.45 | 82.0% | Periplasmic | 2(42–59)(104–121) | Yes |
| 7 | vlhA.1.07 | −10.65 | 68.4% | Extracellular | 2(42–59)(104–121) | No |
| 8 | vlhA.1.08 | −12.84 | 65.5% | Periplasmic | 2(66–83)(126–146) | Yes |
| 9 | vlhA.1.08b | −12.84 | 65.5% | Extracellular | 0 | Yes |
| 10 | vlhA.2.01 | −10.16 | 66.4% | Extracellular | 0 | Yes |
| 11 | vlhA.2.02 | −9.48 | 69.0% | Extracellular | 2(42–59)(104–121) | No |
| 12 | vlhA.3.0.1 | −14.31 | 52.8% | Periplasmic | 0 | Yes |
| 13 | vlhA.3.02 | −9.78 | 67.1% | Extracellular | 0 | Yes |
| 14 | vlhA.3.03 | −10.31 | 68.0% | Extracellular | 2(46–63)(108–125) | No |
| 15 | vlhA.3.04 | −10.86 | 66.4% | Extracellular | 2(46–63)(108–125) | Yes |
| 16 | vlhA.3.05 | −10.04 | 69.3% | Extracellular | 2(46–63)(108–125) | Yes |
| 17 | vlhA.3.06 | −11.47 | 65.8% | Extracellular | 1(9–26) | Yes |
| 18 | vlhA.3.07 | −11.57 | 62.5% | Extracellular | 1(9–26) | Yes |
| 19 | vlhA.3.08 | −10.78 | 66.5% | Extracellular | 1(9–26) | Yes |
| 20 | vlhA.3.09 | −9.09 | 66.2% | Extracellular | 1(9–26) | Yes |
| 21 | vlhA.4.01 | −9.02 | 69.1% | Extracellular | 1(9–26) | No |
| 22 | vlhA.4.02 | −7.77 | 81.5% | Periplasmic | 1(9–26) | Yes |
| 23 | vlhA.4.03a | −10.23 | 66.1% | Outermenbrane | 1(9–26) | Yes |
| 24 | vlhA.4.03b | −12.26 | 66.3% | Extracellular | 0 | Yes |
| 25 | vlhA.4.04 | −12.23 | 60.7% | Extracellular | 2(44–61)(106–123) | Yes |
| 26 | vlhA.4.05 | −10.63 | 66.3% | Extracellular | 2(44–61)(106–123) | Yes |
| 27 | vlhA.4.06 | −10.28 | 67.5% | Extracellular | 2(44–61)(106–123) | Yes |
| 28 | vlhA.4.07 | −10.81 | 66.7% | Extracellular | 2(44–61)(106–123) | Yes |
| 29 | vlhA.4.07.1 | −11.19 | 67.6% | Extracellular | 2(46–63) (108–125) | Yes |
| 30 | vlhA.4.07.2 | −11.85 | 60.6% | Extracellular | 2(66–83) (129–146) | Yes |
| 31 | vlhA.4.07.4 | −9.15 | 68.2% | Extracellular | 2(46–63) (108–125) | Yes |
| 32 | vlhA.4.07.6 | −10.71 | 67.4% | Extracellular | 2(46–63) (108–125) | Yes |
| 33 | vlhA.4.08 | −10.65 | 65.5% | Extracellular | 3(10–27) (44–61) (106–123) | Yes |
| 34 | vlhA.4.09 | −11.45 | 66.5% | Outermenbrane | 2(44–61) (106–123) | Yes |
| 35 | vlhA.4.10 | −7.86 | 81.4% | Periplasmic | 2(44–61) (106–123) | Yes |
| 36 | vlhA4.11 | −10.76 | 65.6% | Extracellular | 2(44–61) (106–123) | Yes |
| 37 | vlhA.4.12 | −10.43 | 67.9% | Outermenbrane | 2(44–61) (106–123) | Yes |
| 38 | vlhA.5.01a | −12.07 | 56.3% | Extracellular | 0 | Yes |
| 39 | vlhA.5.01b | −13.51 | 40.4% | Extracellular | 0 | Yes |
| 40 | vlhA.5.01c | −8.69 | 38.4% | Extracellular | 0 | Yes |
| 41 | vlhA.5.02 | −10.15 | 67.0% | Extracellular | 0 | Yes |
| 42 | vlhA.5.03 | −11.14 | 69.7% | Extracellular | 2(44–61) | Yes |
| 43 | vlhA.5.04 | −10.63 | 70.0% | Extracellular | 2(44–61)(106–123) | Yes |
| 44 | vlhA.5.05 | −9.17 | 69.0% | Extracellular | 2(44–61)(106–123) | Yes |
| 45 | vlhA.5.06 | −9.65 | 67.1% | Extracellular | 1 (19–38) | Yes |
| 46 | vlhA.5.07 | −10.58 | 67.1% | Extracellular | 2(44–61) (106–123) | Yes |
| 47 | vlhA.5.08 | −12.05 | 66.6% | Extracellular | 2(44–61) (106–123) | Yes |
| 48 | vlhA.5.09 | −11.32 | 66.4% | Extracellular | 2(44–61) (106–123) | Yes |
| 49 | vlhA.5.10a | −9.33 | 70.1% | Extracellular | 2(64–81)(127–144) | Yes |
| 50 | vlhA.5.10b | −11.02 | 25.4% | Outermenbrane | 0 | Yes |
| 51 | vlhA.5.11 | −11.26 | 67.6% | Extracellular | 2(44–61)(106–123) | Yes |
| 52 | vlhA.5.12 | −11.73 | 71.3% | Extracellular | 2(44–61)(106–123) | Yes |
| 53 | vlhA.5.13 | −10.82 | 66.4% | Extracellular | 0 | Yes |